source
- AbiVax falls as safety worries cloud ‘landmark’ immune drug resultsA handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.BioPharma Dive · 1mo ago↗ source
- How one state’s medical meal program lowered health care costsMedicaid work requirements, fast-tracked funding for experimental Ebola vaccines, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- #ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutCelcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Executi…Endpoints